GenePath Dx BCR-ABL IS RQ-PCR Kit
CE Approved
- DESCRIPTION: Single-pot duplex assay with integrated reverse transcription (RT) / cDNA synthesis and qPCR. Minimal Residual Disease determination through BCR-ABL/ABL ratio reported on the International Scale (IS) when used in conjunction with the recommended GenePath Dx RNA extraction protocol
- SAMPLE TYPE: EDTA peripheral blood or bone marrow
- REACTION VOLUME: 15 μL
- LIMIT OF DETECTION: 0.0032% of BCR-ABL fusion transcript with ABL transcript used as the reference gene with a logarithmic reduction of 4.49 in relative expression between BCR-ABL and ABL (MR = 4.49).
- WORKFLOW: Uses the ‘UNG/dUTP’ system to minimize the risk of PCR carry-over contamination. The ABL transcript serves as a reference and internal control for monitoring the adequacy of sample and RNA extraction
- INSTRUMENT COMPATIBILITY: Bio-Rad CFX96, Bio-Rad Opus, QIAGEN Rotor-Gene Q, ABI QuantStudio 5, ABI 7500 and Roche Light Cycler 480 II
- RUN TIME: ~ 100 mins
- SOFTWARE: Secure online tool to assist with data analysis and calculate the BCR-ABL/ABL ratio as reported on the IS
GenePath Dx JAK2 v2 Real Time qPCR Test Kit
CE Approved
- DESCRIPTION: Detection of the JAK2 V617F mutation [JAK2:c.G1849T (p.V617F)] in genomic DNA, with standards provided for quantification of % relative Mutant Allele Frequency (MAF)
- SAMPLE TYPE: EDTA peripheral blood or bone marrow
- REACTION VOLUME: 15 μL
- LIMIT OF DETECTION: 1% relative MAF
- WORKFLOW: Single tube
- INSTRUMENT COMPATIBILITY: Two channel assay with broad instrument compatibility
- RUN TIME: ~ 75 mins
- SOFTWARE: Secure online tool to assist with quantification of % relative MAF and data analysis